Regional Drugs Testing Laboratory

Directorate General of Health Services, Guwahati (India) - 781022 Fax: 0361-2338555/2330555 Phone No.0361 2338555

Email:rdtlguwahati@cdsco.nic.in

FORM 13 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

Name of Inspector from whom received

: Mr.R.Vanlalruata, Assistant Director (F and Drugs)

Assistant Director (F&D)

Office of Chief Medical Officer, Aizwal, Mizoram-

India

796017

Serial No. and date of Inspector's memorandum

: MZ/24/A'E'/06 , 15-OCT-2024

Number of Sample

: NIL

Date of receipt

: 01-NOV-2024

Names of drugs purporting to be contained in the sample : Albendazole Tablets IP 400 mg (Albendazole 400)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By	
LSD/GUW/2024- 25/1528	GUW/LS/2024- 25/1556	T-3159	Jan-2024	Dec-2025	Jackson Laboratories Pvt.Ltd, 22-24, Majitha Road, Bye Pass, Amritsar-143 001(India)	
6. Condition of seals on [the packet or on portion of sample or container]			: Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector.			

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing: From 10-Dec-2024 To 07-Jan-2025

COMPOSITION

Each uncoated chewable tablet contains: Albendazole IP 400 mg.

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Off white, elongated, bi-convex, scored on one surface, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Albendazole.	NA
3	Average weight	1.0774 g	NA
4	Uniformity weight of tablet	Complies.	
5	Dissolution	Does not comply.	NLT 80% of claim
6	Level S1 (6 units)	Does not comply. Release of Albendazole of each individual unit is found as follows: Unit 1=55.0%; Unit 2=54.4%; Unit 3=56.9%; Unit 4=56.4%; Unit 5=55.5%; Unit 6=56.4%. Release of Albendazole of all 06 units are found less than 85% of claim i.e. (Q+5%) where Q is 80% of claim.	Each unit is not less than Q+5% i.e., 85% of claim where Q is 80% of claim.

7	Level S2 (6 units)	Does not comply. Release of Albendazole of each individual unit is found as follows: Unit 1=44.3%; Unit 2=47.5%; Unit 3=47.0%; Unit 4=48.2%; Unit 5=49.3% Unit 6=48.5%. Average release of Albendazole of 12 units (S1+S2) is 51.6% of claim which is less than Q i. e. 80% of claim. Release of all 12 units are found less than 65% of claim (Q-15%).	(S1+S2) ≥ 80% of	•
8	Level S3	Out of 12 units all units are found less than 65% of claim (Q-15%) as well as 07 units are found less than 55% of claim (Q-25%)	Average of 24 units(S1+S2+S3) ≥ 80% of claim and not more than two	
			inits are less than 65%c	of
		u de la companya de	laim (Q-15%) and no init is less than 55% of claim (Q-25%)	

Assay Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method	
1	Albendazole	407.14 mg/Tablet	400 mg/Tablet	101.785	92.5 % to 107.5%	I.P. 2022	

In the opinion of the undersigned the sample referred to above is not of standard quality as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample does not conform as per I.P. 2022 with respect to the test for "Dissolution" of Albendazole.

Date: 20-JAN-2025

GOVERNMENT ANALYST Rinku Kalita Government Analyst R.D.T.L., Guwahati-22

Report in red color paper indicates the sample is not of standard quali	ty.
END OF REPORT	